{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:59:33Z","timestamp":1790117973346,"version":"4.0.1"},"reference-count":136,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>High-risk febrile neutropenia (HR-FN) is a life-threatening complication in patients with haematological malignancies or receiving myelosuppressive chemotherapy. Since the last international guidelines were published over 10 years ago, there have been major advances in the understanding and management of HR-FN, including on antibiotic pharmacokinetics and discontinuation\/de-escalation strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Summarizing major advances in the field of antibacterial therapy in patients with HR-FN: empirical therapy, pharmacokinetics of antibiotics and antibiotic stewardship.<\/jats:p><\/jats:sec><jats:sec><jats:title>Sources<\/jats:title><jats:p>Narrative review based on literature review from PubMed. We focused on studies published between 2010 and 2023 about the pharmacokinetics of antimicrobials, management of antimicrobial administration, and discontinuation\/de-escalation strategies. We did not address antimicrobial prophylaxis, viral or fungal infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Content<\/jats:title><jats:p>Several high-quality publications have highlighted important modifications of antibiotic pharmacokinetics in HR-FN, with standard dosages exposing patients to underdosing. These recent clinical and population pharmacokinetics studies help improve management protocols with optimized initial dosing and infusion rules for \u03b2-lactams, vancomycin, daptomycin and amikacin; they highlight the potential benefits of therapeutic drug monitoring. A growing body of evidence also shows that antibiotic discontinuation\/de-escalation strategies are beneficial for bacterial ecology and patients\u2019 outcome. We further discuss methods and limitations for implementation of such protocols in haematology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Implications<\/jats:title><jats:p>We highlight recent information about the management of antibacterial therapy in HR-FN that might be considered in updated guidelines for HR-FN management.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkad166","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T15:47:12Z","timestamp":1685029632000},"page":"2109-2120","source":"Crossref","is-referenced-by-count":20,"title":["Advances in antibacterial treatment of adults with high-risk febrile neutropenia"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2656-1423","authenticated-orcid":false,"given":"Adrien","family":"Contejean","sequence":"first","affiliation":[{"name":"Service d\u2019H\u00e9matologie, Centre Hospitalier Annecy Genevois , 1 Avenue de l\u2019h\u00f4pital, F-74370 Epagny Metz-Tessy , France"},{"name":"\u00c9quipe Mobile d\u2019Infectiologie, AP-HP, APHP.CUP, H\u00f4pital Cochin , F-75014 Paris , France"},{"name":"Universit\u00e9 Paris Cit\u00e9, Facult\u00e9 de M\u00e9decine , F-75006 Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7165-4103","authenticated-orcid":false,"given":"Alexis","family":"Maillard","sequence":"additional","affiliation":[{"name":"\u00c9quipe Mobile d\u2019Infectiologie, AP-HP, APHP.CUP, H\u00f4pital Cochin , F-75014 Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0612-5691","authenticated-orcid":false,"given":"Etienne","family":"Canou\u00ef","sequence":"additional","affiliation":[{"name":"\u00c9quipe Mobile d\u2019Infectiologie, AP-HP, APHP.CUP, H\u00f4pital Cochin , F-75014 Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solen","family":"Kern\u00e9is","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Facult\u00e9 de M\u00e9decine , F-75006 Paris , France"},{"name":"\u00c9quipe de Pr\u00e9vention du Risque Infectieux, AP-HP, H\u00f4pital Bichat , F-75018 Paris , France"},{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM, IAME , F-75018 Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fantin","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Facult\u00e9 de M\u00e9decine , F-75006 Paris , France"},{"name":"D\u00e9partement de M\u00e9decine Interne, AP-HP, H\u00f4pital Beaujon , F-92110, Clichy , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Bouscary","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Facult\u00e9 de M\u00e9decine , F-75006 Paris , France"},{"name":"Service d\u2019H\u00e9matologie, AP-HP, APHP.CUP, H\u00f4pital Cochin , F-75014 Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0786-7518","authenticated-orcid":false,"given":"Perrine","family":"Parize","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses, AP-HP, APHP.CUP, H\u00f4pital Necker-Enfants Malades , F-75015 Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Garcia-Vidal","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital Cl\u00ednic-IDIBAPS , Barcelona , Spain"},{"name":"CIBERINF , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9375-3620","authenticated-orcid":false,"given":"Caroline","family":"Charlier","sequence":"additional","affiliation":[{"name":"\u00c9quipe Mobile d\u2019Infectiologie, AP-HP, APHP.CUP, H\u00f4pital Cochin , F-75014 Paris , France"},{"name":"Universit\u00e9 Paris Cit\u00e9, Facult\u00e9 de M\u00e9decine , F-75006 Paris , France"},{"name":"National Reference Center Listeriosis WHO Collaborating Center, Institut Pasteur , F-75015 Paris , France"},{"name":"Biology of Infection Unit, Inserm U1117 Institut Pasteur , F-75015 Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"2023092801164373900_dkad166-B1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia","volume":"64","author":"Bodey","year":"1966","journal-title":"Ann Intern Med"},{"key":"2023092801164373900_dkad166-B2","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023092801164373900_dkad166-B3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","article-title":"Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines","volume":"76","author":"Mikulska","year":"2018","journal-title":"J Infect"},{"key":"2023092801164373900_dkad166-B4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1200\/JCO.2014.57.2347","article-title":"Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE study","volume":"33","author":"Carmona-Bayonas","year":"2015","journal-title":"J Clin Oncol"},{"key":"2023092801164373900_dkad166-B5","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1002\/cncr.25332","article-title":"Risk of mortality in patients with cancer who experience febrile neutropenia","volume":"116","author":"Lyman","year":"2010","journal-title":"Cancer"},{"key":"2023092801164373900_dkad166-B6","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"2023092801164373900_dkad166-B7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00277-011-1373-2","article-title":"A prospective survey of febrile events in hematological malignancies","volume":"91","author":"Pagano","year":"2012","journal-title":"Ann Hematol"},{"key":"2023092801164373900_dkad166-B8","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/cid\/ciz900","article-title":"Antimicrobial stewardship in a hematological malignancy unit: carbapenem reduction and decreased vancomycin-resistant enterococcus infection","volume":"71","author":"Webb","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023092801164373900_dkad166-B9","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023092801164373900_dkad166-B10","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3324\/haematol.2013.091025","article-title":"European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia","volume":"98","author":"Averbuch","year":"2013","journal-title":"Haematologica"},{"key":"2023092801164373900_dkad166-B11","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients","volume":"18","author":"Klastersky","year":"2000","journal-title":"J Clin Oncol"},{"key":"2023092801164373900_dkad166-B12","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/OP.21.00148","article-title":"Risk-stratifying treatment strategies for febrile neutropenia\u2013tools, tools everywhere, and not a single one that works?","volume":"17","author":"Wijeratne","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"Suppl 1","key":"2023092801164373900_dkad166-B13","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.ijantimicag.2007.06.012","article-title":"Bacteraemia in febrile neutropenic cancer patients","volume":"30","author":"Klastersky","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"2023092801164373900_dkad166-B14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13756-022-01198-5","article-title":"Guidance of empirical antimicrobial therapy by surveillance cultures in high-risk neutropenic patients: a retrospective cohort study","volume":"11","author":"de la Court","year":"2022","journal-title":"Antimicrob Resist Infect Control"},{"key":"2023092801164373900_dkad166-B15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/infdis\/161.3.397","article-title":"The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel","volume":"161","author":"Anon. From the Immunocompromised Host Society","year":"1990","journal-title":"J Infect Dis"},{"key":"2023092801164373900_dkad166-B16","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1086\/522533","article-title":"A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation","volume":"45","author":"Castagnola","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2023092801164373900_dkad166-B17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijid.2016.01.006","article-title":"Differences in characteristics between first and breakthrough neutropenic fever after chemotherapy in patients with hematologic disease","volume":"44","author":"Nam","year":"2016","journal-title":"Int J Infect Dis"},{"key":"2023092801164373900_dkad166-B18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01744-21","article-title":"Impact of empirical antibiotic regimens on mortality in neutropenic patients with bloodstream infection presenting with septic shock","volume":"66","author":"Chumbita","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023092801164373900_dkad166-B19","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac240","article-title":"Bloodstream infections in hematologic malignancy patients with fever and neutropenia: are empirical antibiotic therapies in the United States still effective?","volume":"9","author":"Zimmer","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023092801164373900_dkad166-B20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cmi.2018.07.026","article-title":"Current time-to-positivity of blood cultures in febrile neutropenia: a tool to be used in stewardship de-escalation strategies","volume":"25","author":"Puerta-Alcalde","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2023092801164373900_dkad166-B21","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/jac\/dkac135","article-title":"Resistance to empirical \u03b2-lactams recommended in febrile neutropenia guidelines in gram-negative bacilli bloodstream infections in Spain: a multicentre study","volume":"77","author":"Chumbita","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2023092801164373900_dkad166-B22","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40262-013-0086-1","article-title":"Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations","volume":"52","author":"Goulenok","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"2023092801164373900_dkad166-B23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbmt.2008.10.024","article-title":"Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of gram-negative rods and increasing antibiotic resistance","volume":"15","author":"Mikulska","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023092801164373900_dkad166-B24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jinf.2013.12.006","article-title":"Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients","volume":"68","author":"Mikulska","year":"2014","journal-title":"Journal of Infection"},{"key":"2023092801164373900_dkad166-B25","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3324\/haematol.2013.091330","article-title":"Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)","volume":"98","author":"Averbuch","year":"2013","journal-title":"Haematologica"},{"key":"2023092801164373900_dkad166-B26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106335","article-title":"The place of ceftazidime\/avibactam and ceftolozane\/tazobactam for therapy of haematological patients with febrile neutropenia","volume":"57","author":"Clerici","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2023092801164373900_dkad166-B27","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac079","article-title":"A prospective randomized study comparing ceftolozane\/tazobactam to standard of care in the management of neutropenia and fever in patients with hematological malignancies","volume":"9","author":"Chaftari","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023092801164373900_dkad166-B28","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02292-21","article-title":"Real-life use of ceftolozane\/tazobactam for the treatment of bloodstream infection due to Pseudomonas aeruginosa in neutropenic hematologic patients: a matched control study (ZENITH study)","volume":"10","author":"Bergas","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2023092801164373900_dkad166-B29","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1128\/AAC.02561-14","article-title":"Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia","volume":"58","author":"Rosa","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023092801164373900_dkad166-B30","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1086\/652766","article-title":"How many lumens should be cultured in the conservative diagnosis of catheter-related bloodstream infections?","volume":"50","author":"Guembe","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2023092801164373900_dkad166-B31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.eimc.2019.01.013","article-title":"Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies","volume":"38","author":"Gudiol","year":"2020","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"2023092801164373900_dkad166-B32","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3390\/microorganisms10040733","article-title":"Effect of combination antibiotic empirical therapy on mortality in neutropenic cancer patients with Pseudomonas aeruginosa pneumonia","volume":"10","author":"Albasanz-Puig","year":"2022","journal-title":"Microorganisms"},{"key":"2023092801164373900_dkad166-B33","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/S1473-3099(16)30267-5","article-title":"Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study","volume":"16","author":"Aliberti","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2023092801164373900_dkad166-B34","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1469-0691.2006.01550.x","article-title":"Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the daptomycin surveillance programme (2002\u20132004)","volume":"12","author":"Sader","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"2023092801164373900_dkad166-B35","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/jac\/dkab003","article-title":"Combination of vancomycin plus piperacillin and risk of acute kidney injury: a worldwide pharmacovigilance database analysis","volume":"76","author":"Contejean","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023092801164373900_dkad166-B36","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.cmi.2020.03.019","article-title":"Acute kidney injury following the concurrent administration of antipseudomonal \u03b2-lactams and vancomycin: a network meta-analysis","volume":"26","author":"Bellos","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2023092801164373900_dkad166-B37","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/CCM.0000000000002769","article-title":"Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis","volume":"46","author":"Luther","year":"2018","journal-title":"Crit Care Med"},{"key":"2023092801164373900_dkad166-B38","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s00134-022-06811-0","article-title":"Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study","volume":"48","author":"Miano","year":"2022","journal-title":"Intensive Care Med"},{"key":"2023092801164373900_dkad166-B39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000513742","article-title":"Nephrotoxicity from vancomycin combined with piperacillin-tazobactam: a comprehensive review","volume":"52","author":"Blair","year":"2021","journal-title":"Am J Nephrol"},{"key":"2023092801164373900_dkad166-B40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/cid\/ciu260","article-title":"Development and validation of a clinical model to predict the presence of \u03b2-lactam resistance in viridans group streptococci causing bacteremia in neutropenic cancer patients","volume":"59","author":"Shelburne","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2023092801164373900_dkad166-B41","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00582-2017","article-title":"International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT)","volume":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"},{"key":"2023092801164373900_dkad166-B42","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/resp.12848","article-title":"Clinical features, aetiology and outcome of bacteraemic pneumonia in neutropenic cancer patients","volume":"21","author":"Gudiol","year":"2016","journal-title":"Respirology"},{"key":"2023092801164373900_dkad166-B43","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/CCM.0000000000003687","article-title":"Neutropenic enterocolitis in critically ill patients: spectrum of the disease and risk of invasive fungal disease","volume":"47","author":"Duceau","year":"2019","journal-title":"Crit Care Med"},{"key":"2023092801164373900_dkad166-B44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-3062.2012.00777.x","article-title":"Neutropenic enterocolitis after high-dose chemotherapy and autologous stem cell transplantation: incidence, risk factors, and outcome","volume":"15","author":"Gil","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"2023092801164373900_dkad166-B45","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100944","article-title":"Recent advances in neutropenic enterocolitis: insights into the role of gut microbiota","volume":"54","author":"Kapandji","year":"2022","journal-title":"Blood Rev"},{"key":"2023092801164373900_dkad166-B46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000475589","article-title":"Clinical features and recurrence pattern of perianal abscess in patients with acute myeloid leukemia","volume":"138","author":"Chang","year":"2017","journal-title":"Acta Haematol"},{"key":"2023092801164373900_dkad166-B47","article-title":"Clinical and microbiological characteristics of perianal infections in adult patients with acute leukemia","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"2023092801164373900_dkad166-B48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/cid\/ciy037","article-title":"The impact of reported beta-lactam allergy in hospitalized patients with hematologic malignancies requiring antibiotics","volume":"67","author":"Huang","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023092801164373900_dkad166-B49","first-page":"3209","article-title":"Antibiotic allergy testing improves antibiotic appropriateness in patients with cancer","volume":"73","author":"Trubiano","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023092801164373900_dkad166-B50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/cid\/cix244","article-title":"Impact of an integrated antibiotic allergy testing program on antimicrobial stewardship: a multicenter evaluation","volume":"65","author":"Trubiano","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023092801164373900_dkad166-B51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13223-020-00494-2","article-title":"Practical guide for evaluation and management of beta-lactam allergy: position statement from the Canadian Society of Allergy and Clinical Immunology","volume":"16","author":"Jeimy","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2023092801164373900_dkad166-B52","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jama.2018.19283","article-title":"Evaluation and management of penicillin allergy: a review","volume":"321","author":"Shenoy","year":"2019","journal-title":"JAMA"},{"key":"2023092801164373900_dkad166-B53","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2023.04.008","article-title":"The Dutch working party on antibiotic policy (SWAB) guideline for the approach to suspected antibiotic allergy","author":"Wijnakker","year":"2023.","journal-title":"Clin Microbiol Infect"},{"key":"2023092801164373900_dkad166-B54","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.anai.2021.05.009","article-title":"Association of beta-lactam allergy documentation and antibiotic use in patients with febrile neutropenia","volume":"127","author":"Naureckas Li","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2023092801164373900_dkad166-B55","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1473-3099(08)70228-7","article-title":"Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia","volume":"8","author":"Lortholary","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"2023092801164373900_dkad166-B56","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/FTD.0000000000000346","article-title":"Augmented renal clearance in patients with febrile neutropenia is associated with increased risk for subtherapeutic concentrations of vancomycin","volume":"38","author":"Hirai","year":"2016","journal-title":"Ther Drug Monit"},{"key":"2023092801164373900_dkad166-B57","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1128\/AAC.31.9.1420","article-title":"Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients","volume":"31","author":"Drusano","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"2023092801164373900_dkad166-B58","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/00365540151060941","article-title":"Pharmacokinetics of ceftazidime in febrile neutropenic patients","volume":"33","author":"Nyhl\u00e9n","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"2023092801164373900_dkad166-B59","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1128\/AAC.02340-14","article-title":"Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancy","volume":"58","author":"Sime","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023092801164373900_dkad166-B60","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1128\/AAC.49.12.4934-4941.2005","article-title":"Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies","volume":"49","author":"Buelga","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2023092801164373900_dkad166-B61","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2147\/IDR.S239095","article-title":"A systematic review of vancomycin dosing in patients with hematologic malignancies or neutropenia","volume":"13","author":"He","year":"2020","journal-title":"Infect Drug Resist"},{"key":"2023092801164373900_dkad166-B62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112008","article-title":"Vancomycin dosing in neutropenic patients","volume":"9","author":"Haeseker","year":"2014","journal-title":"PLoS One"},{"key":"2023092801164373900_dkad166-B63","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1128\/AAC.00943-08","article-title":"Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever","volume":"53","author":"Bubalo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2023092801164373900_dkad166-B64","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/AAC.34.5.702","article-title":"Increased aminoglycoside dosage requirements in hematologic malignancy","volume":"34","author":"Zeitany","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"2023092801164373900_dkad166-B65","first-page":"963","article-title":"Alterations in aminoglycoside pharmacokinetics in patients with cancer","volume":"6","author":"Higa","year":"1987","journal-title":"Clin Pharm"},{"key":"2023092801164373900_dkad166-B66","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/infdis\/159.2.281","article-title":"Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models","volume":"159","author":"Leggett","year":"1989","journal-title":"J Infect Dis"},{"key":"2023092801164373900_dkad166-B67","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jac\/27.6.829","article-title":"Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli","volume":"27","author":"Fantin","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"2023092801164373900_dkad166-B68","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1046\/j.1198-743x.2001.00295.x","article-title":"Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters","volume":"7","author":"Jacobs","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"2023092801164373900_dkad166-B69","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","article-title":"Beta-lactam infusion in severe sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis","volume":"42","author":"Abdul-Aziz","year":"2016","journal-title":"Intensive Care Med"},{"key":"2023092801164373900_dkad166-B70","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jac\/dkv288","article-title":"Is prolonged infusion of piperacillin\/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic\/pharmacodynamic and patient outcomes? An observation from the defining antibiotic levels in intensive care unit patients (DALI) cohort","volume":"71","author":"Abdul-Aziz","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2023092801164373900_dkad166-B71","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/38.1.5","article-title":"Is continuous infusion of beta-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations","volume":"38","author":"Mouton","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"2023092801164373900_dkad166-B72","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1128\/AAC.49.12.4920-4927.2005","article-title":"Optimization of meropenem minimum concentration\/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa","volume":"49","author":"Tam","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2023092801164373900_dkad166-B73","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dkf130","article-title":"Pharmacodynamics of cefepime in patients with gram-negative infections","volume":"50","author":"Tam","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2023092801164373900_dkad166-B74","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients\u2014guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique\u2014SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation\u2014SFAR)","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Critical Care"},{"key":"2023092801164373900_dkad166-B75","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1093\/jac\/dkaa359","article-title":"Early therapeutic monitoring of \u03b2-lactams and associated therapy outcomes in critically ill patients","volume":"75","author":"Al-Shaer","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023092801164373900_dkad166-B76","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1093\/jac\/dkz248","article-title":"Parameters influencing the pharmacokinetics\/pharmacodynamics of piperacillin\/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study","volume":"74","author":"Benech","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023092801164373900_dkad166-B77","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/cid\/ciy258","article-title":"Extended vs bolus infusion of broad-spectrum \u03b2-lactams for febrile neutropenia: an unblinded, randomized trial","volume":"67","author":"Ram","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023092801164373900_dkad166-B78","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.medmal.2020.10.019","article-title":"Home intravenous antibiotherapy and the proper use of elastomeric pumps: systematic review of the literature and proposals for improved use","volume":"51","author":"Diamantis","year":"2021","journal-title":"Infect Dis Now"},{"key":"2023092801164373900_dkad166-B79","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.medmal.2016.01.010","article-title":"Preparing and administering injectable antibiotics: how to avoid playing god","volume":"46","author":"Longuet","year":"2016","journal-title":"Med Mal Infect"},{"key":"2023092801164373900_dkad166-B80","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/antibiotics12030568","article-title":"Update on therapeutic drug monitoring of beta-lactam antibiotics in critically ill patients\u2014a narrative review","volume":"12","author":"Sta\u0161ek","year":"2023","journal-title":"Antibiotics"},{"key":"2023092801164373900_dkad166-B81","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ijantimicag.2017.04.008","article-title":"Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens","volume":"50","author":"Rhodes","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2023092801164373900_dkad166-B82","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/phar.1807","article-title":"Pharmacokinetics of cefepime in patients with cancer and febrile neutropenia in the setting of hematologic malignancies or hematopoietic cell transplantation","volume":"36","author":"Whited","year":"2016","journal-title":"Pharmacotherapy"},{"key":"2023092801164373900_dkad166-B83","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3390\/antibiotics10050504","article-title":"Pharmacokinetics and pharmacodynamics of cefepime in adults with hematological malignancies and febrile neutropenia after chemotherapy","volume":"10","author":"\u00c1lvarez","year":"2021","journal-title":"Antibiotics"},{"key":"2023092801164373900_dkad166-B84","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1128\/AAC.49.8.3550-3553.2005","article-title":"Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure","volume":"49","author":"Pea","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2023092801164373900_dkad166-B85","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1093\/jac\/dkaa275","article-title":"A meropenem pharmacokinetics model in patients with haematological malignancies","volume":"75","author":"Contejean","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023092801164373900_dkad166-B86","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ajhp\/54.4.412","article-title":"Stability of meropenem in intravenous solutions","volume":"54","author":"Patel","year":"1997","journal-title":"Am J Health Syst Pharm"},{"key":"2023092801164373900_dkad166-B87","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00228-019-02657-6","article-title":"The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults","volume":"75","author":"Bury","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"2023092801164373900_dkad166-B88","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.medmal.2011.09.014","article-title":"Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia","volume":"41","author":"Hochart","year":"2011","journal-title":"Med Mal Infect"},{"key":"2023092801164373900_dkad166-B89","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3390\/antibiotics11111523","article-title":"Pharmacokinetics of vancomycin among patients with chemotherapy-associated febrile neutropenia: which would be the best dosing to obtain appropriate exposure?","volume":"11","author":"Parra Gonz\u00e1lez","year":"2022","journal-title":"Antibiotics"},{"key":"2023092801164373900_dkad166-B90","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1093\/jac\/dkab278","article-title":"Impact of a vancomycin loading dose on the achievement of target vancomycin exposure in the first 24 h and on the accompanying risk of nephrotoxicity in critically ill patients","volume":"76","author":"Hodiamont","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023092801164373900_dkad166-B91","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.01708-10","article-title":"Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens","volume":"55","author":"Roberts","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2023092801164373900_dkad166-B92","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2023092801164373900_dkad166-B93","first-page":"249","article-title":"Daptomycin use in patients with cancer and neutropenia: data from a retrospective registry","volume":"8","author":"Rolston","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"key":"2023092801164373900_dkad166-B94","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1177\/1060028021991943","article-title":"High-dose daptomycin and clinical applications","volume":"55","author":"Jones","year":"2021","journal-title":"Ann Pharmacother"},{"key":"2023092801164373900_dkad166-B95","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"Suppl A","key":"2023092801164373900_dkad166-B96","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jac\/36.suppl_A.207","article-title":"Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem","volume":"36","author":"Norrby","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"2023092801164373900_dkad166-B97","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1093\/jac\/dku150","article-title":"Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study","volume":"69","author":"Feh\u00e9r","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2023092801164373900_dkad166-B98","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/cir124","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets","volume":"52","author":"Kullar","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023092801164373900_dkad166-B99","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/cid\/ciz051","article-title":"Vancomycin area under the curve and acute kidney injury: a meta-analysis","volume":"69","author":"Aljefri","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023092801164373900_dkad166-B100","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023092801164373900_dkad166-B101","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkr442","article-title":"Continuous versus intermittent infusion of vancomycin for the treatment of gram-positive infections: systematic review and meta-analysis","volume":"67","author":"Cataldo","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2023092801164373900_dkad166-B102","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/jac\/39.6.677","article-title":"Once-daily dosing of aminoglycosides: review and recommendations for clinical practice","volume":"39","author":"Freeman","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"2023092801164373900_dkad166-B103","first-page":"182","article-title":"Extended-interval aminoglycoside therapy for adult patients with febrile neutropenia: a systematic review","volume":"64","author":"Stabler","year":"2011","journal-title":"Can J Hosp Pharm"},{"key":"2023092801164373900_dkad166-B104","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1128\/AAC.42.4.849","article-title":"Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults","volume":"42","author":"Tod","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2023092801164373900_dkad166-B105","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1093\/jac\/dkaa267","article-title":"Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study","volume":"75","author":"Cojutti","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023092801164373900_dkad166-B106","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/jac\/dkv123","article-title":"Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial","volume":"70","author":"Sime","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2023092801164373900_dkad166-B107","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106472","article-title":"Prospective assessment of breakthrough infections and neurotoxicity and their association with cefepime trough concentrations in patients with febrile neutropenia","volume":"59","author":"Gijsen","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2023092801164373900_dkad166-B108","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/cid\/ciac506","article-title":"Beta-lactam antibiotic therapeutic drug monitoring in critically ill patients: a systematic review and meta-analysis","volume":"75","author":"Pai Mangalore","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023092801164373900_dkad166-B109","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrneph.2011.12","article-title":"Antibiotic dosing in critically ill patients with acute kidney injury","volume":"7","author":"Eyler","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"2023092801164373900_dkad166-B110","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40262-020-00968-x","article-title":"Clinical pharmacokinetics of daptomycin","volume":"60","author":"Gregoire","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"2023092801164373900_dkad166-B111","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2023092801164373900_dkad166-B112","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlac080","article-title":"Optimization of antimicrobial dosing in patients with acute kidney injury: a single-centre observational study","volume":"4","author":"Hughes","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2023092801164373900_dkad166-B113","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1128\/AAC.03750-14","article-title":"Propensity-based study of aminoglycoside nephrotoxicity in patients with severe sepsis or septic shock","volume":"58","author":"Picard","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023092801164373900_dkad166-B114","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/jac\/dkv412","article-title":"What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?","volume":"71","author":"Alobaid","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2023092801164373900_dkad166-B115","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01276-16","article-title":"Population pharmacokinetics of piperacillin in nonobese, obese, and morbidly obese critically ill patients","volume":"61","author":"Alobaid","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023092801164373900_dkad166-B116","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1038\/nutd.2014.15","article-title":"Broad-spectrum \u03b2-lactams in obese non-critically ill patients","volume":"4","author":"Hites","year":"2014","journal-title":"Nutr Diabetes"},{"key":"2023092801164373900_dkad166-B117","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11695-011-0586-8","article-title":"Cefepime dosing in the morbidly obese patient population","volume":"22","author":"Rich","year":"2012","journal-title":"Obes Surg"},{"key":"2023092801164373900_dkad166-B118","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/phar.1298","article-title":"Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States","volume":"33","author":"Bookstaver","year":"2013","journal-title":"Pharmacotherapy"},{"key":"2023092801164373900_dkad166-B119","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1472-8206.1991.tb00768.x","article-title":"Pharmacokinetics and ascitic fluid penetration of piperacillin in cirrhosis","volume":"5","author":"Hary","year":"1991","journal-title":"Fundam Clin Pharmacol"},{"key":"2023092801164373900_dkad166-B120","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13756-022-01084-0","article-title":"Antimicrobial stewardship in high-risk febrile neutropenia patients","volume":"11","author":"Contejean","year":"2022","journal-title":"Antimicrob Resist Infect Control"},{"key":"2023092801164373900_dkad166-B121","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s10096-018-3328-1","article-title":"De-escalation and discontinuation strategies in high-risk neutropenic patients: an interrupted time series analyses of antimicrobial consumption and impact on outcome","volume":"37","author":"la Martire","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023092801164373900_dkad166-B122","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(17)30211-9","article-title":"Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (how long study): an open-label, randomised, controlled phase 4 trial","volume":"4","author":"Aguilar-Guisado","year":"2017","journal-title":"Lancet Haematol"},{"key":"2023092801164373900_dkad166-B123","article-title":"Safety & efficacy of antibiotic de-escalation and discontinuation in high-risk haematological patients with febrile neutropenia: a single-centre experience","volume":"9","author":"Verlinden","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023092801164373900_dkad166-B124","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2021.7054","article-title":"Early antibiotic discontinuation or de-escalation in high-risk patients with AML with febrile neutropenia and prolonged neutropenia","volume":"20","author":"Alegria","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2023092801164373900_dkad166-B125","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac005","article-title":"Variation in clinical practice and attitudes on antibacterial management of fever and neutropenia in patients with hematologic malignancy: a survey of cancer centers across the United States","volume":"9","author":"Barreto","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023092801164373900_dkad166-B126","doi-asserted-by":"crossref","first-page":"O453","DOI":"10.1111\/1469-0691.12445","article-title":"Discontinuation of empirical antibiotic therapy in neutropenic acute myeloid leukaemia patients with fever of unknown origin: is it ethical?","volume":"20","author":"Micol","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2023092801164373900_dkad166-B127","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.cmi.2014.10.014","article-title":"Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical","volume":"21","author":"Orasch","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2023092801164373900_dkad166-B128","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13756-020-00729-2","article-title":"Early discontinuation of empirical antibiotic treatment in neutropenic patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome","volume":"9","author":"Niessen","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"2023092801164373900_dkad166-B129","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.cmi.2017.11.009","article-title":"Effect of an antimicrobial stewardship programme on antimicrobial utilisation and costs in patients with leukaemia: a retrospective controlled study","volume":"24","author":"So","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2023092801164373900_dkad166-B130","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/QCO.0000000000000872","article-title":"New approaches to management of fever and neutropenia in high-risk patients","volume":"35","author":"Douglas","year":"2022","journal-title":"Curr Opin Infect Dis"},{"key":"2023092801164373900_dkad166-B131","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1007\/s00259-012-2143-7","article-title":"Use of FDG PET\/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients","volume":"39","author":"Guy","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2023092801164373900_dkad166-B132","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(22)00166-1","article-title":"[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"9","author":"Douglas","year":"2022","journal-title":"Lancet Haematol"},{"key":"2023092801164373900_dkad166-B133","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40506-017-0131-y","article-title":"Improving antimicrobial stewardship in cancer patients through implementation of clinical guidelines","volume":"9","author":"Santarossa","year":"2017","journal-title":"Curr Treat Options Infect Dis"},{"key":"2023092801164373900_dkad166-B134","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3324\/haematol.2013.091769","article-title":"The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients","volume":"98","author":"Gyssens","year":"2013","journal-title":"Haematologica"},{"key":"2023092801164373900_dkad166-B135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40506-019-00189-2","article-title":"Antimicrobial stewardship in patients with hematological malignancies: key considerations","volume":"11","author":"So","year":"2019","journal-title":"Curr Treat Options Infect Dis"},{"key":"2023092801164373900_dkad166-B136","first-page":"1079","article-title":"Reduced mortality from KPC-K.pneumoniae bloodstream infection in high-risk patients with hematological malignancies colonized by KPC-K.pneumoniae","volume":"21","author":"Micozzi","year":"2021","journal-title":"BMC Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/9\/2109\/51782620\/dkad166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/9\/2109\/51782620\/dkad166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T01:40:35Z","timestamp":1702518035000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/9\/2109\/7187543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":136,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,6,1]]},"published-print":{"date-parts":[[2023,9,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad166","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,6,1]]}}}